Pazobrite 200 Tablet
Marketer
Torrent Pharmaceuticals Ltd
Salt Composition
Pazopanib (200mg)
Overview Pazobrite 200 Tablet
Sorafenib 200mg tablets are a targeted therapy, inhibiting protein kinases, indicated for kidney and soft tissue cancers. Optimal absorption requires administration on an empty stomach, consistently at the same time daily. Dosage and frequency are determined individually by your physician, depending on your condition, and may be adjusted. Strict adherence to your doctor's prescription is crucial; incorrect usage or overdosage can lead to severe adverse reactions. Therapeutic benefits may take weeks or months to manifest; discontinue only under your doctor's guidance. Common side effects include elevated blood pressure and diarrhea. Your doctor may recommend regular blood pressure checks. Manage diarrhea with increased fluid intake, or seek medical advice if severe. This medication can lower blood cell counts, increasing infection risk. Report fever, flu-like symptoms, or breathlessness immediately. Prior to commencing treatment, disclose any pre-existing heart, liver, or kidney conditions, and all other medications, particularly anti-infectives, as interactions are possible. This medication is contraindicated during pregnancy and breastfeeding; reliable contraception is essential for both partners throughout treatment.
Primary Ingredients of Pazobrite 200 Tablet
No information provided. Please provide the text you wish me to rephrase.
Uses of Pazobrite 200 Tablet
Renal cell carcinoma/soft tissue sarcoma
Major Benefits of Pazobrite 200 Tablet:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Administer Pazobrite 200 Tablet on an empty stomach.
Common Side effects of Pazobrite 200 Tablet:
- Headache
- Nausea
- Vomiting
- Musculoskeletal (bone, muscle or joint) pain
- Fatigue
- Change in color of hair
- Diarrhea
- High blood pressure
- Decreased appetite
- Weight loss
- Taste change
- Abnormal skin pigmentation
- Hair discoloration
- Tumor pain
- Breathlessness
How to use Pazobrite 200 Tablet:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Administer Pazobrite 200 Tablet on an empty stomach.
How Pazobrite 200 Tablet works:
Pazobrite 200 Tablets function as an anti-neoplastic agent. Its mechanism involves targeting and blocking tyrosine kinase enzyme receptors, crucial for cancer cell multiplication. Concurrently, it limits the development of tumor vasculature, thereby hindering cancer progression.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Pazobrite 200 Tablet is of uncertain safety. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Using Pazobrite 200 Tablets during pregnancy poses a confirmed risk to the fetus. Therefore, it's contraindicated. Nevertheless, in exceptional, life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known hazards. Always seek medical advice.
Breast feedingUNSAFE
Lactation and Pazobrite 200 Tablets are incompatible; the medication poses a potential risk of infant toxicity.
DrivingUNSAFE
Taking Pazobrite 200 Tablets might reduce attentiveness, impair vision, or cause drowsiness and dizziness. Driving should be avoided if these effects are experienced.
KidneySAFE IF PRESCRIBED
Patients with kidney disease can safely use Pazobrite 200 Tablets without requiring any dosage modification.
LiverCAUTION
Patients with liver impairment should use Pazobrite 200 Tablets cautiously, potentially requiring dosage modification under medical supervision. Pazobrite 200 Tablets are contraindicated in individuals with moderate to severe hepatic dysfunction.
What if you forget to take Pazobrite 200 Tablet :
NA
Facts to Know About Pazobrite 200 Tablet
| Label | Value |
|---|---|
| Chemical Type | Diarylalkylamines |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |
| Behavior Class | Kinase inhibitors targeting tyrosine |



